Leisure Acquisition Corp. (NASDAQ:LACQ) announced in an 8-K filing this morning that its shareholders approved its combination with clinical-stage biopharmaceutical company Ensysce Biosciences, Inc. at a special meeting yesterday.
Importantly, investors redeemed just 5,000 shares in connection with the vote and did so at a significant loss as Leisure’s shares traded above $13 throughout June 24, the SPAC’s redemption deadline. They instead redeemed at $10.366 per share, leaving a public SPAC share count of 1,219,268 and approximately $12.64 million in trust.
Leisure initially listed way back in November 2017 with its sights set on hospitality targets, but saw 93.9% of its trust redeemed through four extension votes. It changed course earlier this year as it announced its the $207 million deal with Ensysce on February 1. Ensysce is a clinical-stage biotech company with therapeutics aimed at reducing prescription drug addiction.
All measures on Leisure’s ballot passed by wide margins, but for a full list of proposals and vote tallies, click HERE.
ADVISORS
- Proskauer Rose LLP acted as legal counsel to Leisure.
- Troutman Pepper LLP acted as legal counsel to Ensysce.
Vendome Acquisition Corporation I (NASDAQ:VNMEU) announced the pricing of its $200 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “VNMEU”, Wednesday, July 2, 2025. The new SPAC plans to focus its search on target business in the consumer sector operating in North America, Southeast Asia, and Europe....
Origin Investment Corp. I (NASDAQ:ORIQU) announced the pricing of its $60 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “ORIQU”, Wednesday, July 2, 2025. The new SPAC aims to mount a broad search for a target with a strong management and both revenue and earnings growth potential....
1RT Acquisition Corp. (NASDAQ:ONCHU) announced the pricing of its $150 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “ONCHU”, Wednesday, July 2, 2025. The new SPAC plans to target company in the digital asset ecosystem involved in the creation, storage, exchange or management of such assets, whether...
D. Boral ARC Acquisition II Corp. (NASDAQ:ARBCU) has filed for a $250 million SPAC to give underwriter D. Boral a second in-house SPAC to pursue deals with. The new SPAC offers investors a 1/2 warrant and an initial 18-month time frame to complete a deal. D. Boral II’s sponsor may automatically extend this once by...
Ribbon (NASDAQ:RIBB) has entered into a definitive agreement to combine with Japanese biotech firm DRC Medicine at a pro forma equity value of $422 million. Tokyo-based DRC Medicine manufactures reusable anti-bacterial and anti-allergen wearables and aims to go deeper into the medical device and pharmaceutical space. Transaction Overview Ribbon is expected to provide $50.4 million...